Colorectal Cancer (CRC) Completed Phase 1 Trials for Atezolizumab (DB11595)

Back to Colorectal Cancer (CRC)

Also known as: Malignant Neoplasm of Colorectum / CRC, Colorectal Cancer / Colorectal Cancer / Cancer, Colorectal / CRC (Colorectal Cancer) / Colorectal, Cancer / Colo-rectal Cancer / Colorectal Cancers / A. Colorectal Cancer / Cancer Colorectal / Gastrointestinal Cancers - Colorectal / CRC / CRCS / Malignant colorectal neoplasm / Malignant neoplasm of cecum and/or colon and/or rectum / Malignant neoplasm of caecum and/or colon and/or rectum / Malignant neoplasm of cecum and/or colon and/or rectum (disorder) / Malignant neoplasm of large intestine / Malignant tumor of large intestine / Malignant tumour of large intestine / Malignant neoplasm of large intestine (disorder) / Malignant neoplasm of colon, unspecified / Malignant large intestinal neoplasm NOS / Cancer of large intestine / Malignant neoplasm of large intestine, NOS / Cancer of large bowel / CA - Cancer of large bowel / Colorectal neoplasms malignant / Malignant neoplasm of colon and/or rectum (disorder) / Large intestine carcinoma / Colorectal carcinoma / Colorectal cancer NOS

Indication	Status	Phase
DBCOND0031867 (Colorectal Cancer (CRC))	Completed	1

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT04713891	A Study of KF-0210 in Advanced Solid Tumors Patients	Treatment	Atezolizumab (DB11595) KF-0210 (DB17476)
NCT03289962	A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors	Treatment	Atezolizumab (DB11595) Autogene cevumeran (DB17497)
NCT02876224	Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors	Treatment	Atezolizumab (DB11595) Bevacizumab (DB00112) Cobimetinib (DB05239)
NCT03841110	FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors	Treatment	Aldesleukin (DB00041) Atezolizumab (DB11595) Cyclophosphamide (DB00531) FT500 (DB30080) Fludarabine (DB01073) Nivolumab (DB09035) Pembrolizumab (DB09037)